IVF Plunges 25.00% to Record Low as INVO Fertility Announces Reverse Split to Address Undervaluation

The share price of INVO Fertility (IVF) dropped to a record low on Nov. 26, with an intraday decline of 25.00%. The stock has fallen 21.41% over two trading days, extending a year-long slump that has seen the stock plummet 99.03% since 2024. The decline follows a 1-for-8 reverse stock split announced for Nov. 28, 2025, aimed at addressing extreme undervaluation and stabilizing the stock.

The reverse split, which will reduce shares outstanding from 15 million to 1.89 million, underscores the company’s financial struggles. INVO Fertility’s price-to-sales and price-to-book ratios are at 0.01 and 0, respectively, reflecting severe undervaluation or lack of market confidence. Legal settlements, including a $6 million resolution tied to a Wisconsin Fertility Institute acquisition, and ongoing debt financing—such as a $1.5 million loan amendment—highlight liquidity challenges. High volatility, with an RSI of 33.74 and beta of 3.31, further deters risk-averse investors.

Broader sector risks and weak institutional ownership (0.2%) exacerbate the stock’s woes. The fertility technology market faces regulatory hurdles, reimbursement inconsistencies, and competition from traditional IVF providers. INVO Fertility’s low institutional stake and reliance on private placements signal limited confidence in long-term stability. While the company touts cost advantages for its INVOcell procedure, translating these into market share requires overcoming operational and financial hurdles. Analysts remain cautious, with a target price of $18 amid persistent uncertainty.